tiprankstipranks
Sonnet BioTherapeutics Secures Patent for Cancer Drugs
Company Announcements

Sonnet BioTherapeutics Secures Patent for Cancer Drugs

Don't Miss Our Christmas Offers:

The latest announcement is out from Sonnet BioTherapeutics Holdings ( (SONN) ).

Sonnet BioTherapeutics has secured a U.S. patent for two innovative immunotherapeutic drugs, SON-1411 and SON-1400, which show promise in cancer treatment by enhancing the efficacy of IL-18, a key immune-regulating cytokine. These drugs utilize Sonnet’s FHAB platform to improve stability and target cancer more effectively. The patent, valid until 2044, represents a significant advancement in oncology therapeutics, potentially expanding the application of immunotherapy for cancer patients.

Learn more about SONN stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlySonnet BioTherapeutics reports FY24 EPS ($11.35) vs. ($145.13) last year
TheFlySonnet BioTherapeutics sees cash runway into July 2025
Brian AndersonSONN Earnings this Week: How Will it Perform?
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App